Abviva, Inc. (f/k/a Genesis Bioventures, Inc.) today announced that the
Company will begin trading under its new ticker symbol today –
(OTCBB:AVVA). The Company’s former ticker
symbol was GBIW.OB. The Company will continue to trade on the OTC
Bulletin Board. The Company’s new ticker
symbol was issued by the
Nasdaq following the Company changing its name
from Genesis Bioventures, Inc. to Abviva, Inc.
Genesis Bioventures changed its corporate name to Abviva, Inc. to
emphasize its mission to commercialize the Mammastatin Serum Assay ("MSA”)
and to pursue development of the mammastatin protein as a possible
therapy against breast cancer. The name change was approved by the
shareholders at the 2007 Annual Shareholders Meeting held on September
14, 2007 as part of the Company’s completion
of its reorganization and restructuring plan.
"We determined that the Company requires a
name that represents its mission and commitment to the mammastatin
technology for breast cancer diagnostics and therapeutics,”
said Douglas C. Lane, President and CEO. "Abviva is a name inspired from
a Latin phrase meaning ‘From Life’.
Mammastatin is normally present in healthy women and therefore comes
from life. This technology is used to develop and offer innovative
diagnostic and therapeutic products ‘For Life’,
beginning with the Mammastatin Serum Assay.” About Abviva, Inc.
Abviva is a biomedical company focused on the commercialization of its
owned and licensed assets for breast cancer diagnostics and for breast
cancer therapeutic development.
Statements in this press release that are not strictly historical
facts are "forward-looking" statements (identified by the words
"believe", "estimate", "project", "expect" or similar expressions)
within the meaning of the Private Securities Litigation Reform Act of
1995. These statements inherently involve risks and uncertainties that
could cause actual results to differ materially from the forward-looking
statements. Factors that would cause or contribute to such differences
include, but are not limited to, continued acceptance of the Company's
products and services in the marketplace, competitive factors, changes
in the regulatory environment, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission. The
statements in this press release are made as of today, based upon
information currently known to management, and the Company does not
undertake any obligation to publicly update or revise any
forward-looking statements.
